Ind-Swift Laboratories Reports Strong Q2FY27 Growth Driven by FDF Platform Scale-Up
Ind-Swift Laboratories Ltd · Investor Presentation · 04 Nov 2026, 5:11 pm
Ind-Swift Laboratories Reports Strong Q2FY27 Growth Driven by FDF Platform Scale-Up Ind-Swift Laboratories reported standalone revenue of ₹242.49 crore for Q2FY27, up 25.18% QoQ, with operating EBITDA increasing 27.04% QoQ to ₹42.33 crore (18.02% margin) and PAT reaching ₹31.03 crore. For H1FY27, revenue reached ₹436.20 crore (up 31.83% YoY) and PAT grew 3.3x YoY to ₹55.47 crore. Following its transition to a pure-play Finished Dosage Formulation (FDF) player, the net-debt-free company is funding a ₹250 crore capex via internal accruals, targeting >50% FY27 revenue growth and a medium-term revenue CAGR of 20-25%.
Original exchange filing (PDF)
More announcements from Ind-Swift Laboratories Ltd
- Please find enclosed transcript for earnings call held on November 04, 2026. · 10 Nov 2026
- Audio recording of earning conference call held on 04.11.2026 on un-audited financial results for the quarter ended 30.09.2026. · 05 Nov 2026
- Monitoring Agency Report for the quarter ended September 30, 2026 in respect of receipt of funds raised through preferential issue of 70,00,000 Fully Convertible Warrants · 03 Nov 2026
- Monitoring Agency Report for the quarter ended September 30, 2026 in respect of funds raised through Preferential Issue 2.6 Cr Fully Convertible Warrants · 03 Nov 2026
- Please find enclosed Schedule of Analyst / Investor Meet which will be held on Wednesday, November 04, 2026, at 04.00 P.M. IST in respect of financial results of the Company for the quarter .... · 04 Nov 2026
- Press Release in respect of Unaudited Financial Results (Standalone & Consolidated) for the second quarter and half year ended September 30, 2026 · 30 Oct 2026
- Please refer attached pdf · 30 Oct 2026
- Please refer attached pdf · 30 Oct 2026
